Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials
- 30 April 2013
- journal article
- Published by Elsevier BV in European Urology
- Vol. 63 (4), 717-723
- https://doi.org/10.1016/j.eururo.2012.11.042
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Predictors of cancer-specific mortality after disease recurrence following radical cystectomyBJU International, 2012
- Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urotheliumThe Lancet Oncology, 2010
- Suggestions for Regulatory Agency Approval of Second-Line Systemic Therapy for Metastatic Transitional Cell CarcinomaJournal of Clinical Oncology, 2010
- Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing RegimensJournal of Clinical Oncology, 2010
- Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urotheliumBJU International, 2010
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial TractJournal of Clinical Oncology, 2009
- Vinflunine in platinum‐pretreated patients with locally advanced or metastatic urothelial carcinomaCancer, 2009
- Southwest Oncology Group Phase II Study of Irinotecan in Patients with Advanced Transitional Cell Carcinoma of the Urothelium that Progressed After Platinum-Based ChemotherapyClinical Genitourinary Cancer, 2008
- Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinomaInvestigational New Drugs, 2006
- Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapyCancer, 2001